1. Home
  2. FLGT vs CMPX Comparison

FLGT vs CMPX Comparison

Compare FLGT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$14.26

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.70

Market Cap

926.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLGT
CMPX
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
867.4M
926.7M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
FLGT
CMPX
Price
$14.26
$5.70
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$28.33
$14.43
AVG Volume (30 Days)
310.5K
1.7M
Earning Date
06-01-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,730,000.00
$850,000.00
Revenue This Year
$12.64
N/A
Revenue Next Year
$9.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.57
$1.33
52 Week High
$31.04
$6.88

Technical Indicators

Market Signals
Indicator
FLGT
CMPX
Relative Strength Index (RSI) 15.95 40.19
Support Level N/A $4.78
Resistance Level $19.96 $5.86
Average True Range (ATR) 0.99 0.31
MACD -0.73 -0.12
Stochastic Oscillator 2.02 23.34

Price Performance

Historical Comparison
FLGT
CMPX

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: